RCS - Crystal Amber Fund - Investor Presentation by Morphic Medical Inc

Crystal Amber FundAnnouncement

07/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251007:nRSG3058Ca&default-theme=true

RNS Number : 3058C  Crystal Amber Fund Limited  07 October 2025

7 October 2025

 

Crystal Amber Fund Limited

("Crystal Amber Fund", the "Company" or the "Fund")

 

Investor Presentation by Morphic Medical Inc

 

The Board of Crystal Amber is pleased to announce that Morphic Medical Inc.
("MMI"), the medical device company in which the Fund owns 96.7% of the issued
share capital, will be conducting a live investor presentation via the
Investor Meet Company platform, followed immediately by a Q&A session.

 

This online event will take place at 10:30am on Thursday 16 October 2025.

 

The presentation will be hosted by Mike Gutteridge, MMI's CEO and President,
with opening remarks from Chris Waldron, Crystal Amber's Chairman.

 

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via the Investor Meet Company dashboard up until 15
October 2025, 09:00 BST, or at any time during the live presentation.

 

To register, please visit:
https://www.investormeetcompany.com/crystal-amber-fund-limited/register-investor
(https://www.investormeetcompany.com/crystal-amber-fund-limited/register-investor)

 

Investors who already follow CRYSTAL AMBER FUND LIMITED on the Investor Meet
Company platform will automatically be invited.

 

No new material information will be disclosed during the event. The slides of
the presentation will subsequently be made available on morphicmedical.com
(https://morphicmedical.com/home-2/) .

 

For further enquiries please contact:

 

Sodali & Co - Financial PR adviser to Morphic Medical Inc

Victoria Palmer-Moore / Russ Lynch / Sam Austrums

Tel: 020 7250 1446

morphicmedical@sodali.com (mailto:morphicmedical@sodali.com)

 

Crystal Amber Fund Limited

Chris Waldron (Chairman)

Tel: 01481 742 742

www.crystalamber.com (http://www.crystalamber.com/)

 

Allenby Capital Limited - Nominated Adviser

Jeremy Porter/ Dan Dearden-Williams

Tel: 020 3328 5656

 

Winterflood Investment Trusts - Broker

Joe Winkley/Neil Langford

Tel: 020 3100 0160

 

Crystal Amber Advisers (UK) LLP - Investment Adviser

Richard Bernstein

Tel: 020 7478 9080

 

ABOUT MORPHIC MEDICAL

Morphic Medical
(https://c212.net/c/link/?t=0&l=en&o=4462086-1&h=3398275268&u=https%3A%2F%2Fmorphicmedical.com%2F&a=Morphic+Medical)
 is the developer of RESET®, the first incision-free, endoscopically
delivered therapy designed to treat obesity and related metabolic disorders
such as type 2 diabetes.

RESET is a duodenal-jejunal bypass liner (DJBL) that is implanted and removed
endoscopically, remaining in place for up to nine months. By creating a
temporary barrier in the upper intestine, it has been shown to support
significant weight loss and improved blood sugar control by enhancing natural
gut hormone responses, in a way similar to GLP-1 therapies. Unlike gastric
bypass surgery, RESET is minimally invasive and fully reversible.

RESET addresses a major global health need, with an estimated 93 million
adults in Europe alone living with obesity and type 2 diabetes. It has been
endorsed in the latest clinical guidelines for obesity treatment by both the
European Society for Gastrointestinal Endoscopy (ESGE) and the American
Society for Gastrointestinal Endoscopy (ASGE) - a strong validation from the
medical community.

Founded in 2003, Morphic Medical is headquartered in Boston, Massachusetts.
For more information, please visit morphicmedical.com
(https://morphicmedical.com/) or follow us on X (formerly Twitter
(https://c212.net/c/link/?t=0&l=en&o=4462086-1&h=2521375&u=https%3A%2F%2Ftwitter.com%2FMorphicMedical&a=Twitter)
) and / or LinkedIn
(https://c212.net/c/link/?t=0&l=en&o=4462086-1&h=1416962124&u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmorphic-medical%2F%3FviewAsMember%3Dtrue&a=LinkedIn)
.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPKOBKKBDKBKK